Literature DB >> 1253347

The relationship of myocardial infarct size and prognosis.

J B Caulfield, R Leinbach, H Gold.   

Abstract

Patients with cardiogenic shock were arbitrarily divided into groups, those in whom shock appeared within 6 hours after the onset of acute infarction and those in whom the symptoms appeared more than 6 hours after the onset of acute infarction. The patients with more rapidly developing shock had larger areas of necrosis (average 48%) than the slow-onset group (average 28%). The former group had more sites of total occlusion of the epicardial arteries (3.5 vs 1.6) than the slow-onset group. By postmortem X-ray examination less collateral flow was visible in the rapid-onset shock patients than the slow-onset ones. These observations suggest that slow-onset shock is more likely to respond to presently available therapeutic interventions than the cases with rapid-onset shock.

Entities:  

Mesh:

Year:  1976        PMID: 1253347

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Cardiac resynchronization by cardiosphere-derived stem cell transplantation in an experimental model of myocardial infarction.

Authors:  Michael Bonios; Connie Y Chang; Aurelio Pinheiro; Veronica Lea Dimaano; Takahiro Higuchi; Christina Melexopoulou; Frank Bengel; John Terrovitis; Theodore P Abraham; M Roselle Abraham
Journal:  J Am Soc Echocardiogr       Date:  2011-04-20       Impact factor: 5.251

Review 2.  Stem cells and cardiac repair: a critical analysis.

Authors:  Jonathan H Dinsmore; Nabil Dib
Journal:  J Cardiovasc Transl Res       Date:  2008-01-31       Impact factor: 4.132

Review 3.  Systems approaches to preventing transplanted cell death in cardiac repair.

Authors:  Thomas E Robey; Mark K Saiget; Hans Reinecke; Charles E Murry
Journal:  J Mol Cell Cardiol       Date:  2008-03-19       Impact factor: 5.000

4.  Stacked stem cell sheets enhance cell-matrix interactions.

Authors:  Nikul G Patel; Ge Zhang
Journal:  Organogenesis       Date:  2014-04-25       Impact factor: 2.500

Review 5.  Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation.

Authors:  Angelos Oikonomopoulos; Tomoya Kitani; Joseph C Wu
Journal:  Mol Ther       Date:  2018-03-06       Impact factor: 11.454

Review 6.  Human pluripotent stem cells: Prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair.

Authors:  Matthew E Hartman; Dao-Fu Dai; Michael A Laflamme
Journal:  Adv Drug Deliv Rev       Date:  2015-05-14       Impact factor: 15.470

7.  Stem Cell Therapy in Acute Myocardial Infarction: A Pot of Gold or Pandora's Box.

Authors:  V K Shah; K K Shalia
Journal:  Stem Cells Int       Date:  2011-05-11       Impact factor: 5.443

Review 8.  Stem Cell Technology in Cardiac Regeneration: A Pluripotent Stem Cell Promise.

Authors:  Robin Duelen; Maurilio Sampaolesi
Journal:  EBioMedicine       Date:  2017-01-27       Impact factor: 8.143

9.  Experiences with surgical treatment of ventricle septal defect as a post infarction complication.

Authors:  Kasim Oguz Coskun; Sinan Tolga Coskun; Aron Frederik Popov; Jose Hinz; Jan Dieter Schmitto; Kerstin Bockhorst; Kathrin Monika Stich; Reiner Koerfer
Journal:  J Cardiothorac Surg       Date:  2009-01-06       Impact factor: 1.637

10.  Long-term administration of recombinant canstatin prevents adverse cardiac remodeling after myocardial infarction.

Authors:  Akira Sugiyama; Rumi Ito; Muneyoshi Okada; Hideyuki Yamawaki
Journal:  Sci Rep       Date:  2020-07-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.